Pair the Nox SAS solution with the Nox A1 recorder to capture EEG, EOG, EMG, and ECG signals with high fidelity at home or in the lab.
Key takeaways:
- Nox SAS uses forehead EEG and EMG electrodes, eliminating the need for scalp and chin placements, making it suitable for patients with facial hair, scalp sensitivities, or limited access to trained technicians.
- The system integrates with the Nox A1 recorder to capture EEG, EOG, EMG, and ECG signals, plus respiratory flow via calibrated RIP belts.
- Validated in 6,000+ global sleep studies and a multicenter US study with over 960 participants, it achieved an 85% first-attempt and 88.6% overall success rate for self-applied type II PSG.
- Designed for both in-lab and home use, the solution supports tech-applied and patient-applied setups with seamless integration into Noxturnal Software.
- US launch expands access to full PSG diagnostics in home and lab settings, aiming to improve workflow efficiency and meet rising demand without increasing staff.
Nox Medical has launched the Nox SAS solution in the United States market.
By using forehead-based EEG and EMG electrodes, Nox SAS reduces the need for scalp and chin electrode placement, a streamlined approach that may be particularly helpful for patients with facial hair, scalp sensitivities, or in low-resource environments where trained technicians may be limited.
When paired with the latest Nox A1 recorder, the solution captures EEG, EOG, EMG, and ECG signals with high fidelity and works in tandem with the Nox calibrated RIP belts to deliver Nox Flow (a respiratory flow signal).
“Sleep care is evolving beyond the four walls of the lab,” says Sigurjon Kristinsson, CEO of Nox, in a release. “With Nox SAS, clinicians don’t have to choose between convenience and clinical rigor. This technology delivers both—opening the door to faster workflows, broader access, and better patient experiences.”
Validated in over 6,000 global sleep studies and a multicenter US study of more than 960 participants, Nox SAS achieved 85% first-attempt success rate and 88.6% overall success in self-applied type II PSG testing—without technician support.
“Nox SAS was built to meet the realities of modern sleep care—clinically precise with the simplicity needed to bring full PSG studies into the home,” says Sveinbjorn Hoskuldsson, chief technology officer at Nox, in a release. “By rethinking the traditional PSG setup, we created a solution that delivers gold-standard diagnostics and fits effortlessly into existing workflows.”
Nox SAS Solution Clinical Highlights
- Captures EEG, EMG, and ECG signals with high agreement to manually scored sleep stages in conventional PSG montage
- Validated for both in-lab use and patient-applied type II testing
- Reduces hookup complexity with fewer electrodes, no chin EMG, and tether-free design
- Seamless integration with Noxturnal Software, the same platform used with Nox A1 PSG and Nox T3 HSAT
- Patient-applied and tech-applied hookup instructions available
US Launch
The launch of Nox SAS comes as type II PSG gains momentum as a scalable solution for both expanding access and increasing efficiency.
Nox SAS launched in CE-markets in May 2023. In the United States, it had previously been in use only by academic researchers. Nox SAS is now available for clinical deployment in the United States.
“Whether it’s used in-lab or in the home, Nox SAS allows providers to extend diagnostic capabilities without expanding staff,” says Heidi Riney, MD, ABPN, chief medical officer at Nox, in a release. “This gives clinicians the tools they need to meet growing demand with confidence, accuracy, and ease.”
